Jason Tardio - Feb 3, 2022 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Chief Operating Officer
Signature
/s/ Danielle Mann for Jason Tardio by PoA
Stock symbol
OVID
Transactions as of
Feb 3, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 05:24 PM
Previous filing
Jul 1, 2021
Next filing
Apr 12, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +175K $0.00 175K Feb 3, 2022 Common Stock 175K $2.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.